BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 15936733)

  • 1. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease.
    Saravanan KS; Sindhu KM; Mohanakumar KP
    Brain Res; 2005 Jul; 1049(2):147-55. PubMed ID: 15936733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
    Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
    Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion.
    Sindhu KM; Saravanan KS; Mohanakumar KP
    Brain Res; 2005 Jul; 1051(1-2):25-34. PubMed ID: 15992782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rotenone increases glutamate-induced dopamine release but does not affect hydroxyl-free radical formation in rat striatum.
    Leng A; Feldon J; Ferger B
    Synapse; 2003 Dec; 50(3):240-50. PubMed ID: 14515342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine.
    Sindhu KM; Banerjee R; Senthilkumar KS; Saravanan KS; Raju BC; Rao JM; Mohanakumar KP
    Pharmacol Biochem Behav; 2006 Jun; 84(2):321-9. PubMed ID: 16820197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle.
    Norazit A; Meedeniya AC; Nguyen MN; Mackay-Sim A
    Brain Res; 2010 Nov; 1360():119-29. PubMed ID: 20807515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.
    Testa CM; Sherer TB; Greenamyre JT
    Brain Res Mol Brain Res; 2005 Mar; 134(1):109-18. PubMed ID: 15790535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers.
    Sengstock GJ; Olanow CW; Menzies RA; Dunn AJ; Arendash GW
    J Neurosci Res; 1993 May; 35(1):67-82. PubMed ID: 7685399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra.
    Sengstock GJ; Olanow CW; Dunn AJ; Barone S; Arendash GW
    Exp Neurol; 1994 Nov; 130(1):82-94. PubMed ID: 7529713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute intranigral homocysteine administration produces stereotypic behavioral changes and striatal dopamine depletion in Sprague-Dawley rats.
    Chandra G; Gangopadhyay PK; Senthil Kumar KS; Mohanakumar KP
    Brain Res; 2006 Feb; 1075(1):81-92. PubMed ID: 16487496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease.
    Caboni P; Sherer TB; Zhang N; Taylor G; Na HM; Greenamyre JT; Casida JE
    Chem Res Toxicol; 2004 Nov; 17(11):1540-8. PubMed ID: 15540952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone.
    Fleming SM; Zhu C; Fernagut PO; Mehta A; DiCarlo CD; Seaman RL; Chesselet MF
    Exp Neurol; 2004 Jun; 187(2):418-29. PubMed ID: 15144868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
    Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
    Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium salicylate protects against rotenone-induced parkinsonism in rats.
    Madathil SK; Karuppagounder SS; Mohanakumar KP
    Synapse; 2013 Aug; 67(8):502-14. PubMed ID: 23447126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
    Verma R; Nehru B
    Neurochem Int; 2009 Nov; 55(6):369-75. PubMed ID: 19375462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model.
    Blandini F; Levandis G; Bazzini E; Nappi G; Armentero MT
    Eur J Neurosci; 2007 Jan; 25(2):397-405. PubMed ID: 17284180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-synuclein and tyrosine hydroxylase expression in acute rotenone toxicity.
    Luo C; Rajput AH; Akhtar S; Rajput A
    Int J Mol Med; 2007 Mar; 19(3):517-21. PubMed ID: 17273802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model.
    Saravanan KS; Sindhu KM; Mohanakumar KP
    J Pineal Res; 2007 Apr; 42(3):247-53. PubMed ID: 17349022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
    Alam M; Schmidt WJ
    Behav Brain Res; 2004 Aug; 153(2):439-46. PubMed ID: 15265640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.